A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Renal Cell Carcinoma
Interventions
- DRUG: Evolocumab
- DRUG: Nivolumab
Sponsor
M.D. Anderson Cancer Center
Collaborators
- [object Object]
- [object Object]
- [object Object]